GHENT, Belgium | January 9, 2026 — MRM Health announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for its lead candidate MH002, enabling the launch of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis (UC). The decision marks a critical regulatory milestone for MH002, a Live Biotherapeutic Product (LBP) based on a rationally designed microbial consortium, and positions the program for advanced clinical evaluation across Europe and the United States.
Science Significance
Scientifically, MH002 represents a next-generation microbiome-based therapeutic designed to target disease-specific mechanisms in inflammatory bowel disease. Unlike traditional small molecules or biologics, MH002 consists of a defined combination of six well-characterized commensal bacterial strains, engineered to act synergistically to restore microbiome balance, reduce inflammation, and promote mucosal healing. Earlier Phase 2a data demonstrated a favorable safety profile and encouraging efficacy, including signals of clinical remission and microbiome recovery after eight weeks of treatment. The Phase 2b STARFISH-UC trial is designed to confirm these efficacy signals, refine dosing strategies, and generate robust evidence supporting the therapeutic potential of microbial consortia as a drug class.
Regulatory Significance
The FDA’s IND clearance underscores the growing regulatory acceptance of Live Biotherapeutic Products as rigorously defined and controllable medicines. MH002 is manufactured using MRM Health’s CORAL® platform, which enables scalable, cGMP-compliant production of complete microbial consortia as a single drug substance. This approach addresses historical regulatory concerns around consistency, quality, and reproducibility in microbiome therapies. The STARFISH-UC trial’s randomized, double-blind, placebo-controlled design, combined with a long-term open-label extension, aligns with Good Clinical Practice (GCP) expectations and provides regulators with high-quality data to assess safety, efficacy, and durability of response.
Business Significance
Advertisement
From a business perspective, IND clearance significantly de-risks MH002 and enhances MRM Health’s position as a leader in microbiome-based drug development. The Phase 2b trial will enroll approximately 204 patients, representing a meaningful investment in clinical validation and a key value inflection point for the company. With UC representing a large market characterized by high unmet need and limitations of existing therapies, successful advancement of MH002 could open substantial commercial and partnering opportunities. The milestone also builds on the company’s recent €55 million Series B financing, reinforcing investor confidence in MRM Health’s platform, execution capability, and long-term growth strategy.
Patients’ Significance
For patients living with ulcerative colitis, MH002 offers the promise of a novel, immune-system-sparing, oral therapy that may complement or replace existing treatments associated with systemic immunosuppression or injectable administration. The STARFISH-UC study targets patients inadequately controlled by 5-aminosalicylic acid (5-ASA) with or without low-dose steroids, a population that often faces limited options before escalation to more aggressive therapies. If successful, MH002 could provide a convenient, well-tolerated, one-pill solution that improves quality of life, long-term disease control, and treatment adherence.
Policy Significance
At the policy level, the trial reflects broader momentum toward innovative, microbiome-based interventions that address chronic inflammatory diseases while reducing reliance on long-term immunosuppression. Regulatory agencies and healthcare systems are increasingly prioritizing precision, safety, and sustainability in therapeutic development. MH002’s progress aligns with public health objectives to expand treatment options for IBD, lower cumulative healthcare costs, and encourage advanced manufacturing standards for emerging biologic modalities. The FDA’s IND clearance also signals continued evolution of regulatory frameworks capable of supporting scientifically rigorous microbiome therapeutics.
The FDA’s IND clearance for MH002 and the initiation of the STARFISH-UC Phase 2b trial mark a pivotal step for MRM Health and the broader microbiome therapeutics field. By combining robust clinical design, cGMP-enabled manufacturing, and disease-focused microbial engineering, the company is advancing a differentiated approach to ulcerative colitis treatment. As the study progresses toward enrollment in mid-2026, MH002 stands as a leading example of how innovative science, regulatory readiness, and patient-centric development can converge to shape the future of inflammatory disease care.
Source: MRM Health press release
